Watch for FDA acceptance of the NDA and assignment of a PDUFA date. The confirmatory Phase 3 RESTORE-ALS trial design and enrollment timeline will be key de-risking events. Any FDA communication on the accelerated approval pathway will drive volatility.
Price Chart
Executive Summary
Clene Inc. announced it has submitted a New Drug Application (NDA) to the FDA seeking accelerated approval of CNM-Au8 for the treatment of ALS. The NDA submission is a binary catalyst event for this clinical-stage biotech, with FDA review and potential approval determining the company's near-term trajectory.
Key Facts
- NDA submitted to FDA for CNM-Au8 for ALS treatment
- Submission seeks accelerated approval based on neurofilament light chain biomarker data and clinical outcomes
- Company preparing confirmatory Phase 3 RESTORE-ALS study
- Filing date: October 19, 2026
Financial Impact
No financial figures disclosed in the filing. The NDA submission is a pre-revenue catalyst; approval would open a new commercial market for CNM-Au8 in ALS.
Risk Factors
- FDA may not accept the NDA for filing or may require additional data
- Accelerated approval is not guaranteed; confirmatory trial results may not support full approval
- Clinical-stage biotech with no approved products or disclosed revenue
- Potential need for additional financing to fund commercialization and confirmatory trials
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-032882 |
| Exhibit: ex_1027473.htm | 0001437749-26-032882 |
| Document: 0001437749-26-032882-index-headers.html | 0001437749-26-032882 |
| Document: 0001437749-26-032882-index.html | 0001437749-26-032882 |
| Document: 0001437749-26-032882.txt | 0001437749-26-032882 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $3.73 | awaiting T+20 | — | $3.88 (+4.02%) |
Oct 19, 2026 7d ago | 8-K | $3.29 | awaiting T+20 | — | $3.88 (+17.93%) |
Oct 19, 2026 7d ago | Press Release | $3.29 | awaiting T+20 | — | $3.88 (+17.93%) |
Oct 13, 2026 13d ago | SC 13G/A | $3.39 | awaiting T+20 | — | $3.88 (+14.45%) |
Sep 16, 2026 5w ago | 8-K | $4.15 $3.31 | ▲ +20.36% | ▲ +21.57% | $3.88 (+6.51%) |
Sep 16, 2026 5w ago | 424B5 | $3.86 $3.31 | ▲ +14.25% | ▲ +16.31% | $3.88 (−0.52%) |
Aug 14, 2026 10w ago | 8-K | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.88 (−6.28%) |
Aug 14, 2026 10w ago | Press Release | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.88 (−6.28%) |
Aug 10, 2026 11w ago | 8-K | $5.16 $3.62 | ▼ −29.84% | ▼ −28.93% | $3.88 (−24.81%) |
May 14, 2026 23w ago | 8-K | $7.05 $5.84 | ▼ −17.16% | ▼ −16.30% | $3.88 (−44.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers